EurekAlert! Cancer Research - News Releases

News Releases

Updates every hour. Last Updated: 6-Nov-2025 23:11 ET (7-Nov-2025 04:11 GMT/UTC)

Immunotherapy boosts chemotherapy in combating stage 3 colon cancer

Mayo Clinic
Reports and Proceedings

New research led by Mayo Clinic Comprehensive Cancer Center found that adding immunotherapy to chemotherapy after surgery for patients with stage 3 (node-positive) colon cancer — and with a specific genetic makeup called deficient DNA mismatch repair (dMMR) — was associated with a 50% reduction in cancer recurrence and death compared to chemotherapy alone.

Meeting: 2025 ASCO Annual Meeting

Adding immune checkpoint inhibitor to standard chemotherapy regimen improves outcomes in stage 3 colon cancer, study finds

Dana-Farber Cancer Institute
Reports and Proceedings

Combining standard adjuvant chemotherapy with an immune checkpoint inhibitor (atezolizumab) leads to a significant improvement in disease-free survival in a subset of patients with stage 3 colon cancer that is deficient in DNA mismatch repair (dMMR), Dana-Farber Cancer Institute investigator Dr. Jeffrey Meyerhardt and his colleagues report at the 2025 American Society of Clinical Oncology (ASCO) meeting.

Meeting: 2025 ASCO Annual Meeting

Diet influences survival after stage iii colon cancer, Dana-Farber study finds

Dana-Farber Cancer Institute
Reports and Proceedings

Patients with colon cancer who consumed an anti-inflammatory diet during a phase 3 clinical trial showed longer overall survival post-treatment compared to those on a proinflammatory diet, according to a Dana-Farber Cancer Institute analysis. Engaging in higher levels of physical activity may amplify the positive influence on survival.

Meeting: 2025 ASCO Annual Meeting

Switch to experimental drug after liquid biopsy detection of breast cancer recurrence improves outcomes

Weill Cornell Medicine
Peer-Reviewed Publication

A large prospective, randomized clinical trial in patients with advanced breast cancer has found that the use of liquid biopsy blood tests for early detection of a treatment-resistance mutation, followed by a switch to a new type of treatment, substantially extends the period of tumor control compared to standard care.

Journal: New England Journal of Medicine

Alliance presents results from phase III ATOMIC trial combining atezolizumab with chemotherapy for patients with stage III dMMR colon cancer at ASCO 2025

Alliance for Clinical Trials in Oncology
Peer-Reviewed Publication

The Alliance for Clinical Trials in Oncology announced today results from ATOMIC (A021502), a phase III trial evaluating standard chemotherapy alone or combined with atezolizumab (Tecentriq^®) in treating patients who have surgically resected stage III colon cancer and deficient deoxyribonucleic acid (DNA) mismatch repair (dMMR). The study, sponsored by the National Cancer Institute (NCI) and conducted in partnership with Genentech, a member of the Roche Group, met its primary endpoint, demonstrating a statistically significant improvement in disease-free survival (DFS) with the addition of atezolizumab, an anti-PD-L1 monoclonal antibody, to standard adjuvant FOLFOX (5-fluorouracil, leucovorin, and oxaliplatin). The data are being presented today at 1:05 pm CDT/2:05 pm ET during the Plenary Session at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting (LBA1) by Alliance Study Chair Frank Sinicrope, MD.

Funder: NIH/National Cancer Institute
Meeting: 2025 ASCO Annual Meeting

Dual-target CAR T cell therapy slows growth of aggressive brain cancer

University of Pennsylvania School of Medicine
Peer-Reviewed Publication

A dual-target CAR T cell therapy approach shows promise for slowing tumor growth in a notoriously aggressive and fast-growing brain cancer.

Journal: Nature Medicine
Meeting: 2025 ASCO Annual Meeting

ASCO: Pre-surgical combination therapy boosts survival in patients with rare thyroid cancer

University of Texas M. D. Anderson Cancer Center
Peer-Reviewed Publication

A pre-surgical combination therapy including pembrolizumab plus dabrafenib and trametinib (DTP) significantly improved survival in patients with rare BRAF V600E-mutated anaplastic thyroid cancer (BRAFm-ATC) compared with historical controls, according to new research from The University of Texas MD Anderson Cancer Center.

ADC combination outperforms standard treatment of advanced triple-negative breast cancer

Dana-Farber Cancer Institute
Reports and Proceedings

Dana-Farber Cancer Institute presents potentially practice changing results from the phase 3 ASCENT-04/KEYNOTE-D19 clinical trial at American Society of Clinical Oncology (ASCO) annual meeting

Meeting: 2025 ASCO Annual Meeting

‘Magnificent 7’ combo treatment for pancreatic cancer presented today at international forum by HonorHealth Research Institute

HonorHealth Research Institute
Reports and Proceedings

A new 7-drug treatment for pancreatic cancer dubbed The Magnificent 7 (MAG 7) will be presented today by HonorHealth Research Institute at the 2025 Annual Meeting of the American Society of Clinical Oncology (ASCO), the world's leading professional organization for physicians and oncology professionals caring for cancer patients.

Funder: TGen Pancreas National Advisory Council, Purple Pansies Foundation

Insights from immunotherapy trial inform new approaches to treating advanced skin cancer

University of Pittsburgh
Peer-Reviewed Publication

In patients with an advanced type of skin cancer called cutaneous squamous cell carcinoma, those who received the combination of the immunotherapy drug avelumab and targeted agent cetuximab had almost four times longer median progression-free survival compared to patients who received avelumab alone, according to the results of a phase 2 trial presented today at the American Society of Clinical Oncology (ASCO) meeting and concurrently published in the Journal of Clinical Oncology.

Journal: Journal of Clinical Oncology
Funder: NIH/National Cancer Institute
Meeting: 2025 ASCO Annual Meeting